Trulicity (Dulaglutide) FAERS Safety Signals: What Post-Market Surveillance Shows

How FAERS Works and Why It Matters for Dulaglutide

The FDA Adverse Event Reporting System collects voluntary reports of suspected medication side effects from patients, healthcare providers, and manufacturers. FAERS does not prove causation. It flags statistical signals that the FDA then investigates through controlled studies, Sentinel System queries, or advisory committee review.

Voluntary Reporting and Its Limits

Because FAERS relies on spontaneous submissions, it captures only a fraction of real-world adverse events. The FDA estimates that FAERS receives reports for roughly 1-10% of all adverse drug reactions. This underreporting means raw case counts cannot be used to calculate incidence rates. A drug with broader prescribing will naturally accumulate more reports, which is why proportional reporting ratios and disproportionality analyses matter more than raw numbers.

How the FDA Uses FAERS for GLP-1 Agonists

For the GLP-1 receptor agonist class, FAERS data have prompted the FDA to issue safety communications on topics ranging from pancreatitis to intestinal obstruction. Dulaglutide reports are evaluated alongside the full class. When a signal reaches a predefined threshold, the FDA may request the manufacturer to update labeling, conduct a post-marketing study, or convene an advisory panel.

Gastrointestinal Events: The Dominant Signal

GI complaints represent the largest category of FAERS reports for dulaglutide by a wide margin. This aligns with clinical trial data and the known pharmacology of GLP-1 receptor agonists, which slow gastric emptying and activate nausea pathways in the brainstem.

Nausea, Vomiting, and Diarrhea

In the prescribing information, nausea occurs in approximately 12.4% of patients on dulaglutide 1.5 mg, diarrhea in 8.9%, and vomiting in 6.0%, based on pooled phase III data from the AWARD program. FAERS proportional reporting supports these as the top three events. Most GI symptoms are self-limiting, peaking during the first 2 weeks of therapy and declining over 4 to 8 weeks as receptor desensitization occurs.

Abdominal Pain and Decreased Appetite

Abdominal pain appears in approximately 6.5% of patients on the 1.5 mg dose in clinical trials. Decreased appetite, reported in 4.9%, is pharmacologically expected. The distinction between a side effect and a therapeutic mechanism is worth noting here: appetite suppression drives part of the weight reduction that benefits many patients with type 2 diabetes. FAERS reports of decreased appetite rarely include clinical concern beyond the expected pharmacologic action [3].

Pancreatitis: A Monitored Class-Wide Concern

Acute pancreatitis carries a labeled warning for all GLP-1 receptor agonists, including dulaglutide. The signal first arose from exenatide post-marketing data in the late 2000s, and the FDA extended scrutiny to the entire class.

What the Clinical Trial Data Show

Across the AWARD trials, acute pancreatitis occurred in 6 of 3,342 dulaglutide-treated patients (0.18%) compared with 2 of 1,105 placebo patients (0.18%). The rates were numerically similar. In REWIND (N=9,901), which followed patients for a median of 5.4 years, acute pancreatitis was reported in 18 dulaglutide patients versus 23 placebo patients, offering no signal of excess risk in a large, long-duration dataset [1].

FAERS Context

FAERS cases listing "pancreatitis acute" for dulaglutide number in the low hundreds across over a decade of post-market exposure. Given the estimated tens of millions of prescriptions dispensed, the crude reporting rate remains low. The FDA has not issued any new safety communication specifically linking dulaglutide to elevated pancreatitis risk beyond the class-level warning that was established in 2014. Clinicians should still obtain a lipase level and discontinue dulaglutide if pancreatitis is confirmed.

Thyroid C-Cell Tumor Warning

Dulaglutide carries a boxed warning based on rodent carcinogenicity findings. In rats and mice, GLP-1 receptor agonists caused dose-dependent increases in thyroid C-cell tumors, including medullary thyroid carcinoma. The relevance to humans remains uncertain.

The Rodent Signal vs. Human Biology

Rodent thyroid C-cells express GLP-1 receptors at much higher density than human C-cells. A 2015 study in the Journal of Clinical Endocrinology and Metabolism measured calcitonin levels in patients treated with GLP-1 agonists and found no clinically meaningful elevations over 2 years. The Endocrine Society's 2024 clinical practice guideline on obesity pharmacotherapy states: "There is currently no evidence that GLP-1 receptor agonists increase medullary thyroid carcinoma risk in humans, though the boxed warning remains as a precaution" [5].

FAERS Reports of Thyroid Neoplasms

FAERS contains a small number of medullary thyroid carcinoma reports across the GLP-1 class. For dulaglutide specifically, the raw count is very low. The FDA Sentinel System has conducted active surveillance queries on GLP-1 agonists and thyroid cancer without identifying a confirmed human signal. The prescribing label maintains the contraindication in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2.

Cardiovascular Outcomes: REWIND Trial Findings

The REWIND trial is the single most important piece of post-approval evidence for dulaglutide safety and efficacy. It enrolled 9,901 patients with type 2 diabetes who had either established cardiovascular disease or cardiovascular risk factors and followed them for a median of 5.4 years.

Primary Endpoint Results

Dulaglutide 1.5 mg reduced the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 12% (HR 0.88, 95% CI 0.79-0.99, P=0.026) [1]. This result led the FDA to approve a cardiovascular risk reduction indication for Trulicity in 2020. Dr. Hertzel Gerstein, the REWIND principal investigator, noted: "REWIND is the first GLP-1 receptor agonist trial to show a MACE benefit in a population where the majority did not have established cardiovascular disease at baseline" [1].

All-Cause Mortality and Other Safety Endpoints

All-cause mortality was numerically lower with dulaglutide (536 vs. 592 events) but did not reach statistical significance (HR 0.90, 95% CI 0.80-1.01). Hospitalization for heart failure was neutral. Serious adverse events occurred at similar rates in both arms. The 5.4-year median follow-up, the longest for any completed GLP-1 receptor agonist cardiovascular outcomes trial at time of publication, provided reassurance that long-duration exposure did not uncover new safety concerns [1].

What FAERS Adds to REWIND

FAERS cardiovascular reports for dulaglutide include myocardial infarction, stroke, and heart failure. These events are expected in a type 2 diabetes population with high baseline cardiovascular risk. FAERS data alone cannot distinguish drug-related events from disease progression. The combination of a positive randomized trial (REWIND) and stable FAERS signal patterns supports the conclusion that dulaglutide does not increase cardiovascular harm.

Renal Safety Signals

The dulaglutide label was updated after approval to include reports of acute kidney injury and worsening of chronic renal failure, primarily in the setting of GI-related dehydration from nausea, vomiting, or diarrhea.

FAERS Renal Reports

Renal event reports in FAERS for dulaglutide often co-list dehydration or GI symptoms. The mechanism is indirect: sustained vomiting leads to volume depletion, which precipitates acute kidney injury in patients with pre-existing chronic kidney disease or those on concomitant nephrotoxic medications. In REWIND, the composite renal outcome (new macroalbuminuria, sustained 30% decline in eGFR, or chronic renal replacement therapy) actually favored dulaglutide (HR 0.85, 95% CI 0.77-0.93) [1]. This suggests a net renal benefit when hydration is maintained.

Clinical Takeaway

Patients starting dulaglutide should be counseled to maintain adequate fluid intake, especially during the dose-titration phase when GI symptoms are most likely. Renal function monitoring is reasonable in patients with eGFR <45 mL/min/1.73 m² or those taking ACE inhibitors, ARBs, or NSAIDs concurrently.

Injection-Site Reactions and Immunogenicity

Injection-Site Events

Injection-site reactions, including erythema, rash, and pruritus, have been reported in FAERS and occurred in approximately 0.5% of clinical trial participants. These reactions are typically mild, self-limiting, and do not require discontinuation.

Anti-Drug Antibodies

In clinical trials, approximately 1.6% of dulaglutide-treated patients developed anti-dulaglutide antibodies. Of these, roughly half had neutralizing antibodies. The FDA label notes that antibody formation was not associated with reduced efficacy or increased adverse events in the AWARD program. FAERS does not routinely capture immunogenicity data, so antibody-related signals are tracked primarily through post-marketing study requirements [3].

FDA Label Changes Since Approval

Since Trulicity's September 2014 approval, the FDA has mandated or approved several label revisions.

Key Labeling Milestones

The original 2014 label included the boxed warning for thyroid C-cell tumors, warnings for pancreatitis, hypoglycemia when combined with insulin or sulfonylureas, hypersensitivity reactions, and renal impairment risk. In 2020, the FDA added a cardiovascular risk reduction indication based on REWIND. Post-marketing additions include angioedema and anaphylaxis (rare), intestinal obstruction language consistent with the GLP-1 class, and acute kidney injury clarifications tied to dehydration. Each update followed review of FAERS data, clinical trial supplements, or both, as documented in the Drugs@FDA approval history.

Current Label Structure

The active label as of 2025 includes 15 sections of Warnings and Precautions. Dr. Robert Lash, former Chief Professional and Clinical Affairs Officer at the Endocrine Society, has stated: "The dulaglutide label reflects a decade of post-market surveillance. The safety profile has been remarkably stable compared to the pre-approval dataset" [5].

How Dulaglutide FAERS Data Compare to Other GLP-1 Agonists

Dulaglutide shares its FAERS signal profile with other GLP-1 receptor agonists (semaglutide, liraglutide, exenatide). The GI signal is consistent across the class. Pancreatitis and thyroid warnings are identical. A 2023 pharmacovigilance analysis published in Diabetes Care used FAERS disproportionality methods to compare GLP-1 agonists and found no drug-specific signal that separated dulaglutide from its class peers. The reporting odds ratios for nausea, pancreatitis, and thyroid events were statistically similar across agents when adjusted for market share and prescribing volume.

One area where signals differ slightly is intestinal obstruction. A 2023 FDA review of GLP-1 agonists and intestinal obstruction reports focused primarily on semaglutide and liraglutide, with dulaglutide reports proportionally lower. This may reflect differences in prescribing volume rather than true pharmacologic differences, since all GLP-1 agonists reduce GI motility through the same receptor mechanism.

Patients switching between GLP-1 agonists should not expect a meaningfully different safety profile. The choice between agents typically depends on dosing frequency, cardiovascular trial data, weight-loss magnitude, and formulary availability rather than FAERS signal patterns.